Alzheimer's disease center seeks patients for new drug studies

August 28, 1996

DALLAS, Texas, August 29, 1996 -- Two major drug trials recently initiated at UT Southwestern Medical Center at Dallas may offer hope for the millions of Americans affected by Alzheimer's disease.

UT Southwestern is one of 30 medical centers across the nation -- and the only one in North Texas -- testing propentofylline, an oral drug for Alzheimer's that also may be effective for patients who experience dementia as a result of strokes. If the medication proves effective, it could improve the condition of patients or at least slow the progression of Alzheimer's symptoms, said psychiatry research nurse administrator Doris Svetlik. The most common symptoms of the disease are memory loss, confusion, difficulty in finding the correct words for articulate conversation, difficulty recalling names and repetition of previous conversation.

Researchers at UT Southwestern are hoping to enroll about 15 patients and have set a maximum of 24 patients for the study. The 48-week trial is open to men and women between the ages of 40 and 90. They also must have a relative or friend who can take them to regular appointments and respond to researchers' inquiries.

Another major drug study involves SB202026, which is being tested at 35 sites around the United States. UT Southwestern again is the only North Texas testing center. Researchers expect to enroll about 15 patients in the 24-week trial. The oral medication is intended to alleviate the major symptoms of Alzheimer's. The participants, like those in the propentofylline trial, must be coherent enough to answer researchers' questions.

"We are encouraged by the number of new medications being developed for Alzheimer's," said Dr. Myron Weiner, vice chairman for clinical services in psychiatry, assistant professor of neurology, holder of the Aradine S. Ard Chair in Brain Science and director of the clinical core of the National Institutes of Health-funded Alzheimer's Disease Center. "We are hopeful that these new drugs will prove beneficial to at least some of the patients who experience the devastating symptoms of Alzheimer's."

Svetlik said the clinic also has several other drug trials under way. Only one Alzheimer's medication, Cognex, has received approval from the Food and Drug Administration. About 25 percent of Alzheimer's patients can tolerate an adequate dose of Cognex, and a quarter of those have shown improvement, Svetlik said.

"After Cognex was approved, we had difficulty recruiting for other drug studies because everyone wanted to be on that drug," she said. "We're now starting to get more interest in these new studies as people realize that one drug doesn't work for everybody."

The cause of Alzheimer's is still a mystery although researchers have made progress in understanding the role played by genes. The new generation of medications target various sections of the brain that degenerate during the course of the disease.

Alzheimer's disease affects approximately 4 million Americans. The UT Southwestern clinic currently sees about 300 patients.

For more information about the new drug studies and other clinic research, call (214) 648-8696.

UT Southwestern Medical Center

Related Medication Articles from Brightsurf:

New medication may treat underlying causes of hypertrophic cardiomyopathy
Mavacamten, a new investigational cardiac medication, may improve heart function for people with thickened heart muscle leading to obstructed blood flow through the heart, a condition known as obstructive hypertrophic cardiomyopathy.

Therapy plus medication better than medication alone in bipolar disorder
A review of 39 randomized clinical trials by scientists from UCLA and their colleagues from other institutions has found that combining the use medication with psychoeducational therapy is more effective at preventing a recurrence of illness in people with bipolar disorder than medication alone.

Kids diagnosed with ADHD often don't take medication regularly
Children diagnosed with ADHD inconsistently take their prescribed medication, going without treatment 40 per cent of the time, a new study has found.

Long-term medication for schizophrenia is safe
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.

Which is more effective for treating PTSD: Medication, or psychotherapy?
A systematic review and meta-analysis led by Jeffrey Sonis, MD, MPH, of the University of North Carolina School of Medicine, finds there is insufficient evidence at present to answer that question.

ADHD medication: How much is too much for a hyperactive child?
When children with ADHD don't respond well to Methylphenidate (MPH, also known as Ritalin) doctors often increase the dose.

Pain medication use by children after common surgeries
About 400 caregivers reported pain medication use by children after common surgeries such as hernia, elbow fracture, appendectomy or adenoid removal in this study.

Bringing cancer medication safely to its destination
Treating cancer more selectively and more effectively -- this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU).

Bullying linked to student's pain medication use
In a school-based survey study of all students in grades 6, 8, and 10 in Iceland, the use of pain medications was significantly higher among bullied students even when controlling for the amount of pain they felt, as well as age, gender, and socioeconomic status.

New medication gives mice bigger muscles
Researchers from Aarhus University, Denmark, have studied a new group of medicinal products which increase the muscle- and bone mass of mice over a few weeks.

Read More: Medication News and Medication Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to